Abstract:Oncology drug discovery and development has always been an area facing many challenges. Phase 1 oncology studies are typically small, open-label, sequential studies enrolling a small sample of adult patients (i.e., 3-6 patients/cohort) in dose escalation. Pediatric evaluations typically lag behind the adult development program. The pediatric starting dose is traditionally referenced on the recommended phase 2 dose in adults with the incorporation of body size scaling. The size of the study is also small and dependent upon the prevalence of the disease in the pediatric population. Similar to adult development, the dose is escalated or de-escalated until reaching the maximum tolerated dose (MTD) that also provides desired biological activities or efficacy. The escalation steps and identification of MTD are often rule-based and do not incorporate all the available information, such as pharmacokinetic (PK), pharmacodynamic (PD), tolerability and efficacy data. Therefore, it is doubtful if the MTD approach is optimal to determine the dosage. Hence, it is important to evaluate whether there is an optimal dosage below the MTD, especially considering the emerging complexity of combination therapies and the long-term tolerability and safety of the treatments. Identification of an optimal dosage is also vital not only for adult patients but for pediatric populations as well. Dosage-finding is much more challenging for pediatric populations due to the limited patient population and differences among the pediatric age range in terms of maturation and ontogeny that could impact PK. Many sponsors defer the pediatric strategy as they are often perplexed by the challenges presented by pediatric oncology drug development (model of action relevancy to pediatric population, budget, timeline and regulatory requirements). This leads to a limited number of approved drugs for pediatric oncology patients. This review article provides the current regulatory landscape, incentives and how they impact pediatric drug discovery and development. We also consider different pediatric cancers and potential clinical trial challenges/opportunities when designing pediatric clinical trials. An outline of how quantitative methods such as pharmacometrics/modelling & simulation can support the dosage-finding and justification is also included. Finally, we provide some reflections that we consider helpful to accelerate pediatric drug discovery and development.

A review of dose escalation for FDA-approved products treating solid tumors and hematological malignancies in first-in-human trials

Three steps towards dose optimization for oncology dose finding

Adaptive Dose Modification for Phase I Clinical Trials

Dose Optimization of Targeted Therapies for Oncologic Indications

A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities

Designing Dose-Optimization Studies in Cancer Drug Development: Discussions with Regulators

Oncology Dose Selection in Subsequent Indications: What Can We Learn From FDA-approved Oncology Drugs?

A seamless phase II/III design with dose optimization for oncology drug development

AIDE: Adaptive intrapatient dose escalation designs to accelerate Phase I clinical trials

Application of quantitative pharmacology analysis to support early clinical development of oncology drugs: dose selection

Dose Finding in Oncology Trials Guided by Ordinal Toxicity Grades Using Continuous Dose Levels

Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse

An Innovative Approach to Optimize First-In-Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T-Cell Engagers: Experience from A Solid Tumor Bispecific T-Cell Engager

Dose Optimization for Novel Oncology Agents: Design Options and Strategies

Dose Finding with Escalation with Overdose Control (EWOC) in Cancer Clinical Trials

Pediatric oncology drug development and dosage optimization

Seamless Phase II/III Design: a Useful Strategy to Reduce the Sample Size for Dose Optimization

Dose Individualization for Phase I Cancer Trials With Broadened Eligibility

Statistical operating characteristics of current early phase dose finding designs with toxicity and efficacy in oncology

Adaptive phase I–II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies

An Evaluation of First-in-Human Studies for RNA Oligonucleotides